Supernus Pharmaceuticals (FRA:S49) E10: €1.30 (As of Mar. 2026)


FRA:S49 Supernus Pharmaceuticals Inc FRA:S49
86 GF Score
Price €39.20
GF Value €33.96
Valuation Fairly Valued
View Full Analysis

What is Supernus Pharmaceuticals E10?

Supernus Pharmaceuticals FRA:S49 -1.01% 86 E10 is €1.30 as of Mar. 2026. GuruFocus rates FRA:S49 with a GF Score™ of 86/100 and a GF Value™ of €33.96 (Fairly Valued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.035. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €1.30 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Supernus Pharmaceuticals's average E10 Growth Rate was -3.10% per year. During the past 3 years, the average E10 Growth Rate was 17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Supernus Pharmaceuticals was 44.50% per year. The lowest was 17.60% per year. And the median was 31.05% per year.

As of today (2026-06-28), Supernus Pharmaceuticals's current stock price is €39.20. Supernus Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was €1.30. Supernus Pharmaceuticals's Shiller PE Ratio of today is 30.15.

During the past 13 years, the highest Shiller PE Ratio of Supernus Pharmaceuticals was 79.92. The lowest was 17.35. And the median was 29.25.


Supernus Pharmaceuticals  (FRA:S49) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Supernus Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=39.20/1.30
=30.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Supernus Pharmaceuticals was 79.92. The lowest was 17.35. And the median was 29.25.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Supernus Pharmaceuticals E10 Related Terms


Supernus Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals E10 Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.88 1.23 1.58 1.33

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.38 1.32 1.33 1.30

FRA:S49 vs BCRX, PBH, ANIP: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Shiller PE Ratio falls into.


FRA:S49
86GF Score
Supernus Pharmaceuticals Inc FRA:S49
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.035/330.2130*330.2130
=-0.035

Current CPI (Mar. 2026) = 330.2130.

Supernus Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 0.160 241.018 0.219
201609 1.051 241.428 1.438
201612 0.246 241.432 0.336
201703 0.178 243.801 0.241
201706 0.285 244.955 0.384
201709 0.243 246.819 0.325
201712 0.220 246.524 0.295
201803 0.397 249.554 0.525
201806 0.488 251.989 0.639
201809 0.446 252.439 0.583
201812 0.422 251.233 0.555
201903 0.301 254.202 0.391
201906 0.540 256.143 0.696
201909 0.490 256.759 0.630
201912 0.558 256.974 0.717
202003 0.362 258.115 0.463
202006 0.577 257.797 0.739
202009 0.628 260.280 0.797
202012 0.469 260.474 0.595
202103 0.092 264.877 0.115
202106 0.357 271.696 0.434
202109 0.340 274.310 0.409
202112 0.035 278.802 0.041
202203 0.390 287.504 0.448
202206 0.132 296.311 0.147
202209 0.030 296.808 0.033
202212 0.406 296.797 0.452
202303 0.271 301.836 0.296
202306 -0.018 305.109 -0.019
202309 -0.272 307.789 -0.292
202312 0.016 306.746 0.017
202403 0.000 312.332 0.000
202406 0.334 314.175 0.351
202409 0.622 315.301 0.651
202412 0.258 315.605 0.270
202503 -0.194 319.799 -0.200
202506 0.347 322.561 0.355
202509 -0.682 324.800 -0.693
202512 -0.060 324.054 -0.061
202603 -0.035 330.213 -0.035

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €1.30 mean?
Supernus Pharmaceuticals (FRA:S49) has a E10 of €1.30 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' E10 too high?
Supernus Pharmaceuticals' current E10 is €1.30. Overall, Supernus Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' E10 compare to BCRX and PBH?
Supernus Pharmaceuticals' E10 of €1.30 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current E10 is €1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (FRA:S49) is currently considered Fairly Valued. The stock's GF Value™ is €33.96, compared to a current price of €39.20 — trading 15.4% above its estimated fair value. The current E10 is €1.30. Supernus Pharmaceuticals' overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Supernus Pharmaceuticals (FRA:S49), the current E10 is €1.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (FRA:S49) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of €39.20 is trading 15.4% above its estimated GF Value™ of €33.96. GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:S49:

  • E10: €1.30
  • GF Value™: €33.96 vs. price of €39.20 (15.4% above fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the FRA:S49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USA0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
86GF Score

Get the complete analysis for FRA:S49

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.20
Price
€33.96
GF Value